Participate in your choice of CME/CE symposia at the 2016 Congress. Symposia that include meals or refreshments are events that fill up quickly. You may preregister during your initial conference registration, or log into your CMHC account.
Faculty: David Joyce MD, MBA
Capital requirements are a given in any healthcare professional’s practice, but these are not skills taught in medical school education and thus, these decisions are often left to administrative employees who may or may not have the knowledge or understanding either. Attendees will leave this session better able to:
This activity has been approved for 1 AMA PRA Category 1 Credits™
Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress
Faculty: Paul A. Gurny, MBA, MS
Good leadership skills are essential to build a successful practice. As a healthcare professional, how you lead impacts your ability as a provider and eventually, the quality, safety, and cost of the care you are giving your patients. But good leadership is a learned skill! Attendees will leave this session better able to:
This activity has been approved for 1 AMA PRA Category 1 Credits™
Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress
Faculty: James A. Underberg, MD
One of the many challenges posed to clinicians today is that of the recognition, diagnosis and care of patients with rare diseases. The educational goals of this workshop are to raise clinician awareness about the prevalence of certain rare lipid disorders, and improve their diagnostic and therapeutic capabilities. Nationally recognized experts will discuss the prevalence of HoFH, LAL-D, FCS, and inherited forms of lipodystrophy, and the diagnostic and treatment challenges associated with them. Case studies will be presented to highlight the issues associated with these rare lipid disorders. A concluding panel discussion and audience question-and-answer session will reinforce key concepts and help clinicians understand how to effectively diagnose and manage rare lipid disorders to improve patient outcomes and reduce the risk of mortality when these disorders are undetected.
Learning Objectives
Supported in part by an educational grant from Alexion Pharmaceuticals, Inc. Endorsed by the FH Foundation.
Faculty: Stephen Devries, MD, FACC
Although it is well known that poor nutrition contributes to the development of most chronic conditions, including cardiovascular and metabolic diseases, many US medical schools still fail to adequately prepare future physicians for everyday nutrition challenges in clinical practice. In this symposium, Dr. Stephen Devries, Executive Director of the Gaples Institute for Integrative Cardiology, will provide an overview of diet for the primary prevention of conditions such as CVD and diabetes and discuss diet as adjunct for the treatment of established disease. Dr. Devries will also explain how to overcome obstacles to nutrition counseling in a busy practice, describe the use of rapid dietary assessment tools and utilization of motivational interviewing for nutritional goal setting, and provide strategies to implement one nutritional intervention at a time.
Learning Objectives
Supported by educational funding from Tarsus Cardio Inc. dba Cardiometabolic Health Congress.
Faculty: Steven E. Nissen, MD, MACC (Chair); Michael H. Davidson, MD; Robert H. Eckel, MD
This symposium is designed to update clinicians on the identification and diagnosis, as well as current guidelines and emerging algorithms for the treatment of statin intolerant patients. The efficacy and safety of current and emerging therapies for statin intolerant patients will also be reviewed during the symposium. Expert faculty will discuss the true incidence and diagnostic criteria of statin intolerance, the mechanistic rationale for lowering LDL-C through PCSK9 inhibition and other novel targets/pathways, treatment strategies, and where emerging therapies fit into current treatment guidelines and algorithms. Attendees will also have the opportunity to gain practical clinical perspective from an expert roundtable discussion on a statin intolerant patient case. This symposium is expected to improve lipid management of patients at increased ASCVD risk, particularly those with statin intolerance.
Learning Objectives
Supported in part by educational funding donations provided by Amgen and Esperion Therapeutics, Inc.
Faculty: Michael Emmett MD, MACP; Stephen Gottlieb, MD
This workshop will address the diagnosis and management of hyponatremia in HF patients by incorporating patient case examples into didactic presentations. Expert faculty will outline the major underlying causes of hyponatremia in HF patients, the 2013 EPR guidelines and differential algorithms for diagnosis, the safety and efficacy of current treatment options, and the complexities of HF to take into consideration when individualizing treatment. Multidisciplinary consultation will also be addressed to demonstrate the benefits of different perspectives in the diagnosis and treatment of these patients. Expert faculty will engage learners on these topics through a case-based format and stimulate practical clinical problem solving through a series of questions pertaining to the case. Finally, experts will provide clinicians with the ability to integrate diagnostic strategies into clinical practice and select treatment options for HF patients with hyponatremia in order to optimize patient outcomes.
Learning Objectives
Supported by an educational grant from Otsuka America Pharmaceutical Inc.
Faculty: Bernard Zinman, MD (Chair); Athena Philis-Tsimikas, MD; Anne Peters, MD; Jean-François Yale, MD
Despite well-established treatment guidelines, many patients with T2DM are not managed optimally and fail to achieve recommended levels of blood glucose control. Delays in initiating insulin, however, are common and may stem from both physician and patient barriers. Negative patient perceptions regarding insulin include complicated dosing regimens, fear of injections, and hypoglycemia. Clinician concerns include hypoglycemia, weight gain, and the misconception that elevated insulin increases cardiovascular risks.
This symposium will bring clinicians up to date on the latest available and emerging options in basal insulin therapy, alone and in combination with other antidiabetic agents. To help clinicians address the unmet needs of patients in this area, expert faculty will discuss common barriers to the initiation of and adherence to insulin therapy as well as strategies to overcome these barriers, including how to help patients successfully utilize new insulin delivery systems and technology designed to make therapy simpler and more convenient.
Learning Objectives
Supported by an educational grant from Novo Nordisk.
Faculty: Christie M. Ballantyne, MD (Chair); Henry A. Ginsberg, MD; James A. Underberg, MD; Michael J. Koren, MD
During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Attendees will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.
Learning Objectives
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals.
Faculty: Christie M. Ballantyne, MD (Chair); Peter Libby, MD; Paul M. Ridker, MD
This educational activity is designed to update clinicians on the role of inflammation in the development and progression of atherosclerosis, the utilization of inflammatory biomarkers in assessing patients for secondary CVD risk, and the use of current and novel agents for the treatment of inflammation for secondary prevention of CVD risks. Expert faculty will engage in a roundtable discussion on these topics and present brief overviews on the pathogenesis of inflammation in atherosclerosis, the American College of Cardiology (ACC)/American Heart Association (AHA) 2013 guidelines and the National Lipid Association (NLA) Recommendations for the Patient-Centered Management of Dyslipidemia for the use of inflammatory biomarkers in patient assessment for secondary CVD risks, and evidence demonstrating the pleiotropic effects of statins and benefits and risks of current and novel agents for the treatment of inflammation in the prevention of secondary CVD risks. This symposium is expected to bring more focus to the role of inflammation in the initiation and progression of atherosclerosis and as a treatment target for patients at risk.
Learning Objectives
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Faculty: Deepak L. Bhatt, MD, MPH (Chair); Elaine M. Hylek, MD, MPH; Christian T. Ruff, MD, MPH
This symposium will address clinical practice gaps and educational needs with didactic presentations and interactive case-based discussions regarding the updated 2014 AHA/ACC/HRS guideline recommendations for NVAF, the safety and efficacy of NOACs in patients with NVAF and comorbidities associated with metabolic syndrome, current and emerging reversal agents for NOACs, and recent regulations and processes for reimbursement designed to improve post-discharge adherence to anticoagulation/ antithrombotic treatment plans and reduce hospital readmissions.
Learning Objectives
Supported in part by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Faculty: George L. Bakris, MD (Chair); Rajiv Agarwal, MD; Joann Lindenfeld, MD; Robert Toto, MD
Management of patients who are at chronic risk for hyperkalemia frequently include dietary modifications and/or discontinuation of specific medications that confer renal and/or cardiac protection. Weighing the risk of hyperkalemia against the risk of discontinuing reno- and cardio-protective therapies can present a paradox to clinicians treating hyperkalemia. Although the short-term management of hyperkalemia can be very effective, the utility of current strategies to manage hyperkalemia is limited, with no long-term outcome data to guide in the management of this condition. New therapies to manage hyperkalemia are currently available and under development that may provide safer, more consistent management.
This symposium will review the most up-to-date clinical evidence on these new and potential therapies for the long-term management of hyperkalemia to improve guideline adherence and help clinicians move toward providing appropriate management for hyperkalemic patients with CKD, diabetes mellitus (DM), and/or HF by assessing risk profiles and customizing regimens based on individual patient needs.
Learning Objectives
Supported by an educational grant from Relypsa, Inc.
Faculty: Clyde W. Yancy, MD, Msc (Chair); Keith C. Ferdinand, MD; Javed Butler, MD, MPH
This symposium will address knowledge and competency gaps surrounding HF prevention and management with a didactic presentation outlining the risk of HF in patients with cardiometabolic disease in order for HCPs to identify patients who may benefit from screening and if necessary the early initiation of HF treatment. Experts also explain the underlying genetic causes for racial disparities in HF and how biomarkers can assist physicians in predicting survival rates. Expert faculty will also review the 2013 ACCF/AHA guidelines to facilitate the appropriate use of guideline-directed pharmacotherapy recommendations in clinical practice. Additionally, this symposium will provide an overview of the different therapeutic classes of agents used to treat heart failure including recently approved therapies. To help clinicians differentiate and select among the various treatment options, patient cases will also be presented so that clinicians can gain experience selecting treatment regimens that optimize patient outcomes.
Learning Objectives
Supported by an educational grant from Arbor Pharmaceuticals, LLC and Metabolic Medical Institute.
Faculty: Jay S. Skyler, MD (Chair); Robert E. Ratner, MD; Robert H. Eckel, MD; Julio Rosenstock, MD
Combining GLP-1RAs with basal insulin provides complementary action, lowering both PPG and FPG, to improve glycemic control in T2DM. The weight-sparing effect of GLP-1RAs makes them well suited for use in patients with concerns about insulin-induced weight gain. This symposium will discuss the use of insulin and GLP-1RA combinations to achieve glycemic control and potentially reduce cardiometabolic risk.
Learning Objectives
Supported by an educational grant from Sanofi-Aventis U.S.
Back to 11th Annual CMHC Home